<DOC>
	<DOCNO>NCT00280540</DOCNO>
	<brief_summary>This double-blind study evaluate reduction systolic blood pressure use therapy initiate valsartan 160 mg valsartan + hydrochlorothiazide ( HCTZ ) 160/12.5 mg compare conventional approach ( therapy initiate low-dose valsartan 80 mg ) .</brief_summary>
	<brief_title>Efficacy Safety Valsartan/Hydrochlorothiazide Combination Therapy Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male female age 18 old Diagnosed hypertension ( mean seat systolic blood pressure ≥ 150 mm Hg &lt; 180 mm Hg mean seat diastolic blood pressure ≥ 90 mm Hg &lt; 110 mm Hg ) Patients severe hypertension : Systolic ≥ 180 mm Hg Diastolic ≥ 110 mm Hg History secondary hypertension ( include primary aldosteronism , renovascular hypertension , pheochromocytoma etc . ) History myocardial infarction , stroke [ e.g . cerebrovascular accident ( CVA ) , thrombotic stroke , transient ischemic attack ( TIA ) ] , onset heart failure within last 6 month . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>High blood pressure</keyword>
	<keyword>Blood pressure control</keyword>
	<keyword>Blood pressure reduction</keyword>
	<keyword>Valsartan</keyword>
</DOC>